Who founded Chrysalis Biotherapeutics?

Chrysalis Biotherapeutics was founded by Darrell H. Carney, Laurie Sower.

How much funding has Chrysalis Biotherapeutics raised?

Chrysalis Biotherapeutics has disclosed $515K raised across 1 round.

Where is Chrysalis Biotherapeutics headquartered?

Chrysalis Biotherapeutics is headquartered in Galveston, US.

Chrysalis Biotherapeutics

Galveston, US · Delaware corporation

Find your way into Chrysalis Biotherapeutics

178 people in our graph share verified history with the Chrysalis Biotherapeutics team — schools, employers, funds. One of them is your warm intro.

Russ Nashunlockedknows Darrell H. Carney · together at University of Connecticut (overlapped)

×11knows the team · via University of Connecticut

Chrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.

Biotech Healthtech

Founders & leadership

Darrell H. Carney inPhDDarrell H. Carney is a biochemist who spent over 30 years as a professor at the University of Texas Medical Branch, conducting research on thrombin receptors and peptide-based tissue regeneration before founding Chrysalis BioTherapeutics in 2012 to develop therapeutics targeting radiation exposure and, more recently, acute respiratory distress syndrome.

Laurie SowerPhD

Jerry BatyJD, CPA, MBA

Lauri SowerNamed on SEC filing

Timothy SchmidtMBA

Marie RobbNamed on SEC filing

Jeffery SheldonMBA

Board

Gerald M FullerPhD

Steven PikulinPhD

James T. RyabyPhD

Reported raises · per SEC filings

Form D private placements

$515K disclosed across 1 round · 2023

▶$515KraisedMar 2024 · 12 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Lauri SowerExecutive Officer
Darrell CarneyExecutive Officer, Director
Timothy SchmidtDirector
James RyabyDirector
Marie RobbDirector
Jeffery SheldonDirector

Offering amount: $3M
Amount sold: $515K
Minimum investment: $10K
Proceeds to insiders: $139K
First sale: Nov 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

IQVIA35 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Krystalbio30 shared keywordsKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.

Fortis Life Sciences26 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.

Eli Lilly25 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies competing with Chrysalis Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Chrysalis Biotherapeutics do?: Chrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.
Who founded Chrysalis Biotherapeutics?: Chrysalis Biotherapeutics was founded by Darrell H. Carney, Laurie Sower.
How much funding has Chrysalis Biotherapeutics raised?: Chrysalis Biotherapeutics has disclosed $515K raised across 1 round.
Where is Chrysalis Biotherapeutics headquartered?: Chrysalis Biotherapeutics is headquartered in Galveston, US.